- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.
Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Pfizer CT.gov Call Center
- Puhelinnumero: 1-800-718-1021
- Sähköposti: ClinicalTrials.gov_Inquiries@pfizer.com
Opiskelupaikat
-
-
-
Daegu, Etelä -Korea
- Rekrytointi
- Site KR01113
-
Seongnam-si, Etelä -Korea
- Rekrytointi
- Site KR01063
-
Seoul, Etelä -Korea
- Rekrytointi
- Site KR01065
-
Seoul, Etelä -Korea
- Rekrytointi
- Site KR01084
-
-
-
-
Quebec
-
Chicoutimi, Quebec, Kanada
- Rekrytointi
- Site CA01194
-
Montreal, Quebec, Kanada
- Rekrytointi
- Site CA01071
-
Montreal, Quebec, Kanada
- Rekrytointi
- Site CA01052
-
-
-
-
-
Kaohsiung City, Taiwan
- Rekrytointi
- Site TW01117
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Yhdysvallat, 72211
- Rekrytointi
- Arkansas Urology
-
-
California
-
Santa Barbara, California, Yhdysvallat, 93105
- Rekrytointi
- Samsun Clinic - Ridley-Tree Cancer Center
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80012
- Rekrytointi
- Rocky Mountain Cancer Center
-
-
Delaware
-
Newark, Delaware, Yhdysvallat, 19713
- Rekrytointi
- Medical Oncology Hematology Consultants
-
-
Illinois
-
Hinsdale, Illinois, Yhdysvallat, 60521
- Rekrytointi
- Hope and Healing Clinical Research LLC
-
New Lenox, Illinois, Yhdysvallat, 60451
- Rekrytointi
- Hope and Healing Clinical Research LLC
-
Niles, Illinois, Yhdysvallat, 60714
- Rekrytointi
- Illinois Cancer Specialists
-
-
Indiana
-
Fort Wayne, Indiana, Yhdysvallat, 46825
- Rekrytointi
- Fort Wayne Medical Oncology and Hematology
-
-
Michigan
-
Royal Oak, Michigan, Yhdysvallat, 48073
- Rekrytointi
- Comprehensive Urology
-
-
Missouri
-
Columbia, Missouri, Yhdysvallat, 65201
- Rekrytointi
- Missouri Cancer Associates
-
St Louis, Missouri, Yhdysvallat, 63110
- Rekrytointi
- Siteman Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Yhdysvallat, 89106
- Rekrytointi
- Comprehensive Cancer Centers of Nevada - Southwest
-
-
New York
-
New York, New York, Yhdysvallat, 10029
- Rekrytointi
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Fairfield, Ohio, Yhdysvallat, 45014
- Rekrytointi
- Oncology Hematology Care Clinical Trials, LLC
-
-
Oregon
-
Eugene, Oregon, Yhdysvallat, 97401
- Rekrytointi
- Williamette Valley Cancer Institute and Research Center
-
Tigard, Oregon, Yhdysvallat, 97223
- Rekrytointi
- Compass Oncology - West
-
-
Tennessee
-
Nashville, Tennessee, Yhdysvallat, 37203
- Rekrytointi
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Yhdysvallat, 78705
- Rekrytointi
- Texas Oncology
-
Tyler, Texas, Yhdysvallat, 75702
- Rekrytointi
- Texas Oncology - Northeast Texas
-
-
Virginia
-
Charlottesville, Virginia, Yhdysvallat, 22903
- Rekrytointi
- University of Virginia Comprehensive Cancer Center
-
Norfolk, Virginia, Yhdysvallat, 23502
- Rekrytointi
- Virginia Oncology Associates
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
- Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
- Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
- Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria:
- Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
- Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
- Prior pelvic radiation for any reason
- Inadequate bladder function
- Other active malignancies within 3 years prior to randomization
- Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
- Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
- Uncontrolled diabetes
- Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
- Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
- Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
- Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
- Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
- Active keratitis or corneal ulcerations
- History of autoimmune disease that has required systemic treatment in the past 2 years
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Prior allogeneic stem cell or solid organ transplant
- Received a live attenuated vaccine within 30 days prior to randomization
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Arm A
Enfortumab vedotin + pembrolizumab (EV + P) |
Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.
Muut nimet:
IV infusion on Day 1 of every 3-week cycle up to cycle 17.
Muut nimet:
|
|
Active Comparator: Arm B
Concurrent Chemoradiotherapy (cCRT) |
64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes. 55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only. 40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation. 500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.
Muut nimet:
12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.
Muut nimet:
100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Aikaikkuna: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Overall Survival (OS)
Aikaikkuna: Up to approximately 60 months
|
Time from randomization to death due to any cause. |
Up to approximately 60 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Aikaikkuna: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Aikaikkuna: Up to approximately 60 months
|
cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology. |
Up to approximately 60 months
|
|
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Aikaikkuna: Up to approximately 60 months]
|
Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first. |
Up to approximately 60 months]
|
|
Time to Cystectomy
Aikaikkuna: Up to approximately 60 months
|
The time from randomization to cystectomy. |
Up to approximately 60 months
|
|
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Aikaikkuna: Up to approximately 60 months
|
The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Cystectomy Free Survival (CFS)
Aikaikkuna: Up to approximately 60 months
|
The time from randomization to cystectomy or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Aikaikkuna: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
|
Number of Participants with Serious TEAEs
Aikaikkuna: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Opintojohtaja: Zejing Wang, MD/PhD, Pfizer
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
- Gemsitabiini
- Neoplasmat
- Virtsarakon kasvaimet
- Uroteelinen karsinooma
- Sisplatiini
- Pembrolitsumabi
- Fluorourasiili
- Komplikaatiot
- Urologiset sairaudet
- Uroteelin syöpä
- Enfortumabi vedotiini
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Urologiset kasvaimet
- Naisten virtsa- ja sukupuolielinten sairaudet
- Miesten urogenitaaliset sairaudet
- Lihasinvasiivinen virtsarakon syöpä
- Mitomysiini
- Virtsarakon sairaudet
- Virtsarakon säilyttäminen
- Urogenitaaliset sairaudet
- Female Urogenital Diseases and Pregnancy
- Bladder-sparing
Muita asiaankuuluvia MeSH-ehtoja
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Neoplasmat histologisen tyypin mukaan
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Karsinooma
- Urogenitaaliset sairaudet
- Neoplasmat
- Urologiset sairaudet
- Virtsarakon kasvaimet
- Urologiset kasvaimet
- Karsinooma, siirtymäsolu
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Miesten urogenitaaliset sairaudet
- Virtsarakon sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet
- Orgaaniset kemikaalit
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Heterosykliset yhdisteet, 2-rengas
- Heterosykliset yhdisteet, sulatettu rengas
- Terapeuttiset lääkkeet
- Indolit
- Epäorgaaniset kemikaalit
- Klooriyhdisteet
- Typpiyhdisteet
- Deoksisytidiini
- Syytidiini
- Pyrimidiininnukleosidit
- Pyrimidiinit
- Urasiili
- Pyrimidinonit
- Platinayhdisteet
- Sädehoito
- Kinonit
- Atsiriinit
- Annos fraktiointi, säteily
- Sädehoidon annos
- Mitomysiinit
- Indolekki
- Gemsitabiini
- Fluorourasiili
- Sisplatiini
- Mitomysiini
- pembrolitsumabi
- enformab vedotiini
- Säteilyannoksen hypofraktiointi
Muut tutkimustunnusnumerot
- C5701009
- EV-309 (Muu tunniste: Alias Study Number)
- 2026-525612-34-00 (Ctis)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .